AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02810470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel Cream
Description: Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
Study NCT02541669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-491
Description: TAK-491 tablets
Study NCT02541669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-491 placebo
Description: TAK-491 placebo-matching tablets
Study NCT02541669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-491 placebo
Description: TAK-491 placebo-matching tablets
Study NCT00343785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00343785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study NCT00343785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO
Study NCT00343785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic bone marrow transplantation
Study NCT00343785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00343785 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies
Study NCT00343785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT00343785 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study NCT00343785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04421560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Capsule, taken by mouth daily
Study NCT04421560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given as an intravenous injection through a vein (IV) every 3 weeks
Study NCT04421560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given as infusion into a vein (intravenous, IV)
Study NCT03837366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity tracker and health coaching
Description: Use of an activity tracker alone or in combination with health coaching on physical activity behaviors.
Study NCT03837366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity tracker and health coaching
Description: Use of an activity tracker alone or in combination with health coaching on physical activity behaviors.
Study NCT01486472 — intervention group
Intervention type: DRUG
Intervention: S-1
Description: Adjuvant S-1 chemotherapy will be performed to GC patients receiving curative D2 gastric surgery
Study NCT01562301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 by vein 7 days after Anvirzel administration in a 21 dayc cycle.
Study NCT01562301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by vein 7 days after Anvirzel administration in a 21 day cycle.
Study NCT01562301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anvirzel
Description: Starting Cohort Dose: 6 mg/m2 given 3 times a day administered sublingually for a 21 day cycle.~Expansion Cohort Starting Dose: Maximum tolerated dose from
Study NCT01562301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
Study NCT01684579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Resistance exercise will be performed 2 days per week for 18 weeks. The resistance training protocol will follow the Resistance Training Strategies for Individuals With Cancer (RTSFIC). The goals will be to keep intensity levels low at the outset (having lighter weights and more reps) and progress slowly and safely. Training prescriptions will be modified based on the training level of the patients and their progress.
Study NCT01684579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: A 20-week aerobic walking exercise program will be developed for each participant based on results of initial exercise testing and prescribed to be done 5 or more days per week designed to progress from moderate exercise intensity, (50-70% maximum heart rate), to vigorous exercise intensity (75-85% maximum heart rate). Maximum heart rate (HR max) will be determined as the peak heart rate achieved during initial cardiopulmonary exercise screening. Heart rate during exercise will be monitored by participants using wrist monitors, already available through TREC Program. Patient progress will also be evaluated using a six minute walk test (6MWT), which will be conducted at TGP at baseline, 6, 12 and 18 weeks and, after completion of the intervention.
Study NCT01684579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Group Counseling
Description: The psychosocial component of the 20-week exercise program includes a 1 ½ hour support group offered prior to one of the weekly exercise classes.
Study NCT03747315 — intervention group
Intervention type: OTHER
Intervention: In vitro functional test
Description: Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.
Study NCT03747315 — intervention group
Intervention type: OTHER
Intervention: In vitro functional test
Description: Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on samples from healthy subjects who donated their blood to the French Blood Establishment.
Study NCT03075345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: Four sessions of the ACT protocol will be psychoeducational in nature, with brief experiential exercises in the class and in-between session practice. It's aim is to allow individuals to be able to sit with difficult experiences (rather than fight against them) and in turn this may allow them to live towards what they value in life.
Study NCT03075345 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (dietetic intervention)
Description: Six sessions of a dietetic intervention will be psychoeducational in nature around weight and nutrition, delivered by professionals working in the service.
Study NCT03075345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (dietetic intervention)
Description: Six sessions of a dietetic intervention will be psychoeducational in nature around weight and nutrition, delivered by professionals working in the service.
Study NCT02642003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony Stimulating Factor
Study NCT03014128 — intervention group
Intervention type: OTHER
Intervention: Clinical examination and data processing of questionnaires
Description: xy
Study NCT04403646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ARBOX
Description: dry extract of polyphenols (tannins) form quebracho and chestnut 240 mg, B12 vitamin 0.72 µg
Study NCT04403646 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for ARBOX
Study NCT00740909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: A therapy designed to help patients with response prevention skills.
Study NCT02889198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go NAP SACC
Description: Go NAP SACC is a suite of online tools designed to help child care programs improve their nutrition environment. Tools include: self-assessment, goal setting, action planning, and tips and materials. In addition to these online tools, local technical assistance providers offer center directors an orientation on how to use Go NAP SACC and minimal ongoing technical assistance.
Study NCT03309657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Description: This is an observational pharmacokinetic study whereby patients received a single dose of ceftolozane/tazobactam and plasma and cerebrospinal fluid samples were subsequently collected and analyzed to described the pharmacokinetics.
Study NCT02144480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive training
Description: The IT group will receive physiotherapy twice daily with longer duration and higher intensity
Study NCT02144480 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: traditional training
Description: usual care: conventional rehabilitation
Study NCT00754208 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: methylphenidate
Description: Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.
Study NCT03687372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101
Description: hydrogen peroxide topical solution 45%
Study NCT03687372 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vehicle
Description: vehicle as a topical solution
Study NCT03891862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Study NCT02309177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02309177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02309177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01698086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation: balance and eye movement exercises
Description: The Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions. The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report. The balance training includes standing and walking tasks on varied types of compliant surfaces, base of support, head movements, visual input and eye-hand tasks. The tasks will progress from simple to more complex. Eye movement exercises will include voluntary saccadic eye movements and smooth pursuit movements. Vestibulo-ocular eye training will be performed while visually fixating on a stationary object, while moving the head up and down and side to side at various speeds, progressing from sitting to standing on firm and compliant surface. Participants in the Experimental group will be given items of the exercise program to perform as a home exercise program.
Study NCT04180839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gaming-related retrieval-extinction
Description: During one training session,participants will first view a 5-min retrieval video containing gaming content and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole training includes 2 training sessions. Participants will receive one training session once a day for two consectutive days.
Study NCT04180839 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: nongaming-related retrieval-extinction
Description: During one session,participants will first view a 5-min neutral video and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole procedure includes 2 sessions. Participants will receive one session once a day for two consectutive days.
Study NCT02469077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
Study NCT02469077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone
Description: In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
Study NCT02469077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxone
Description: In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
Study NCT03891862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: non-active dosage form
Study NCT03946683 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cyberknife for Early Stage Breast Cancer
Description: Utilization of Cyberknife Robotic Radiosurgery as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer
Study NCT03279549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine dressing change
Description: Through regular dressing changes to clean the wound, reduce bacterial growth in the wound and protect the wound. In recent years, nano-silver ion gel and dressings are widely used in burns, which effectively reduced the risk of wound infection and beneficial for wound healing. This technique is widely used in clinic.
Study NCT03279549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited debridement & Acellular dermal matrix dressing
Description: In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. The xenogeneic acellular dermal matrix dressing has a better protective effect on burn wound after debridement. After covering, the wound will remain alive for about two weeks, providing a good microenvironment for wound repair.
Study NCT03279549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited debridement & Epidermal cell spraying
Description: In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. Epidermal cell spraying technology is a brand new method to rapidly collect epidermal cells from patients themselves and then used on their wounds. The recipient site is 40-80 times than the donor site.
Study NCT03279549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited debridement & Basic fibroblast growth factor
Description: In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. BFGF is a kind of polypeptide capable of promoting the growth of fibroblasts, and it also promotes the proliferation, differentiation and migration of epidermal cells. Studies have shown that bFGF could significantly improve the healing of burn wounds.
Study NCT00636194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb Multipurpose Solution
Description: daily care of contact lenses
Study NCT00636194 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alcon OptiFree Replenish Multipurpose Solution
Description: daily care for contact lenses
Study NCT01940315 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rBV A/B
Description: 0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days
Study NCT01940315 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (USP sterile saline for injection)
Description: 0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days
Study NCT03784092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: feedback
Description: feedback by electronic pedometers regarding patient mobility while undergoing labor induction
Study NCT03192540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will undergo an exercise protocol once a week, for eight weeks. Exercise will be continuous for one hour.
Study NCT00810082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiveStep
Description: ActiveStep™ is a training simulator. The system uses a computer-controlled treadmill to recreate life-like dynamic balance challenges such as slipping and tripping in a safe, controlled environment.
Study NCT00810082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy for Fall Prevention
Description: Standard physical therapy for fall prevention
Study NCT00810082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physical Therapy for Fall Prevention
Description: Standard physical therapy for fall prevention
Study NCT02995733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PARTICS using QVAR
Description: Patient takes inhaled corticosteroid at the time of rescue inhaler use
Study NCT03802487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study NCT03802487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-microtracer
Description: Pharmaceutical form: Solution for injection~Route of administration: Intravenous
Study NCT03802487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Charcoal
Description: Pharmaceutical form: Granules for suspension~Route of administration: Oral
Study NCT05550077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography
Description: Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography
Study NCT05550077 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous transluminal angioplasty and stenting
Description: Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.
Study NCT04572919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral advancement flap
Description: Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
Study NCT04572919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic Limberg flap
Description: Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
Study NCT01760018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane group
Description: anesthesia is maintained with desflurane and remifentanil (Desflurane group)
Study NCT01760018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA group
Description: anesthesia is maintained with fresofol and remifentanil (TIVA group).
Study NCT01232309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chitin-Glucan
Description: 3 x 500 mg capsules (tid) = 4.5 mg daily dose
Study NCT01232309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Chitin-Glucan
Description: 3 x 167 mg capsules (tid) = 1.5 g daily dose
Study NCT01232309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose Chitin-Glucan + Olive Extract
Description: 3 x 167 mg capsules (tid) = 1.5 g daily dose (C-G) + 135 mg olive extract
Study NCT01232309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 500 mg capsules (tid)
Study NCT02524132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Study NCT00910637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: 55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 13 cycles